Focused On-demand Library for Mortality factor 4-like protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UBU8

UPID:

MO4L1_HUMAN

Alternative names:

MORF-related gene 15 protein; Protein MSL3-1; Transcription factor-like protein MRG15

Alternative UPACC:

Q9UBU8; B4DKN6; B7Z6R1; D3DW88; O95899; Q5QTS1; Q6NVX8; Q86YT7; Q9HBP6; Q9NSW5

Background:

Mortality factor 4-like protein 1, also known as MORF-related gene 15 protein, Protein MSL3-1, and Transcription factor-like protein MRG15, plays a pivotal role in transcriptional activation through its involvement in the NuA4 histone acetyltransferase complex. This complex is crucial for acetylation of histones H4 and H2A, altering nucleosome-DNA interactions and facilitating transcription regulation. Additionally, it contributes to DNA repair, apoptosis, and DNA damage response through its association with the mSin3A complex and involvement in homologous recombination repair.

Therapeutic significance:

Understanding the role of Mortality factor 4-like protein 1 could open doors to potential therapeutic strategies.